|Bid||1,315.00 x 240300|
|Ask||1,400.00 x 53000|
|Day's range||1,322.00 - 1,338.00|
|52-week range||1,064.91 - 1,387.89|
|PE ratio (TTM)||15.09|
|Earnings date||27 Jul 2017|
|Dividend & yield||0.31 (1.82%)|
|1y target est||17.31|
Royston Wild looks at two stock stars that could deliver brilliat long-term earnings growth.
Nearly a third of shareholders in Burberry voted against the luxury goods company's executive pay report on Thursday, despite a move by its new finance chief Julie Brown to head off the opposition by foregoing a share options award worth up to 2.4 million pounds ($3.11 million). Investor (LSE: 0NC5.L - news) groups had raised concerns about pay both for creative director and former chief executive Christopher Bailey and for Brown ahead of the annual general meeting, the first for new chief executive Marco Gobbetti. In the event Burberry saw off a revolt on the scale it suffered in 2014, when a majority of shareholders voted against Bailey's pay.
The world's top medical technology companies are turning to robots to help with complex knee surgery, promising quicker procedures and better results in operations that often leave patients dissatisfied. Demand for artificial replacement joints is growing fast, as baby boomers' knees and hips wear out, but for the past 15 years rival firms have failed to deliver a technological advance to gain them significant market share.